国家和28省(区、市)医保药品目录复合药收载情况分析

Analysis of Compound Drugs Recorded in the National Drug Reimbursement List and Provincial Drug Reimbursement Lists in 28 Provinces (Regions and Municipalities) of China

目的:为复合药的遴选及管理提供参考。方法:对国家医保药品目录和各省(区、市)医保药品目录增补品种所收载的复合药的品种数和收录频次进行统计分析,采用Spearman检验法对品种数和当地经济发展水平进行相关性分析。结果:国家医保药品目录共收载复合药126个品种,涵盖了19个药物类别;发布了乙类医保药品目录的28省(区、市)基本医保乙类药品增补品种目录中,复合药增补品种从19种到50种不等,发布了复合药增补品种或异名库的24省(区、市)复合药增补品种从12种到117种不等;接近50%的药品仅被单个省(区、市)收载,绝大部分复合药纳入各省(区、市)为1~4频次。增补的复合药品种数同本省(区、市)人均国内生产总值(GDP)水平无关(P>0.05,r=-0.180)。结论:各地区复合药增补品种数与当地经济发展水平关系不大;复合药收载工作进度不一、数量差异较大且分散度高。建议在国家层面明确复合药概念,制定统一管理政策,规范复合药的遴选标准,保障患者的临床用药需求。

OBJECTIVE：To provide reference for the selection and management of compound drugs. METHODS：The variet-ies and frequency of compound drugs recorded in the national drug reimbursement list and drug reimbursement list supplementary varieties in provinces （regions and municipalities） were statistically analyzed,and Spearman test method was used to conduct the correlation analysis for the variety and local economic development level. RESULTS：There were totally 126 varieties of compound drugs recorded in the national drug reimbursement list,covering 19 categories. The varieties of compound drugs in class B supple-mentary drug lists of 28 provinces （regions and municipalities） ranged from 19 to 50;for the supplementary lists of compound drugs in 24 provinces（regions and municipalities）,the varieties ranged from 12 to 117. Almost 50% of the compound drugs were recorded in only 1 province（region and municipality）,and most compound drugs recorded 1-4 time（s）in provinces（regions and municipalities）. There was no significant relationship between the varieties number of supplementary compound drugs and the per capita GDP in a province（region and municipality）（P〉0.05,r=-0.180）. CONCLUSIONS：The supplementary variety of com-pound drugs in a region has little relationship with the local economic development level. The work progress of recoding the com-pound drugs varies a lot,with large differences in number and high dispersion. It is necessary to clarify the definition of compound drug at a national level,develop unified management policies,standardize the selection criteria for compound drugs and guarantee the clinical medication requirements of patients.